A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Trial details
- Registry ID
- NCT07067463
- Drugs studied
- Orelabrutinib
TrialRedline tracks 6 clinical trials sponsored by Zenas BioPharma (USA), LLC: 4 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisNCT07067463 | Orelabrutinib | Recruiting | 2030-06Estimated |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisNCT07299019 | Orelabrutinib | Recruiting | 2030-06Estimated |
| A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)NCT05786573 | Obexelimab | Active not recruiting | 2026-06-30Estimated |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseNCT05662241 | Obexelimab | Active not recruiting | 2025-11-13Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Obexelimab in Patients With Systemic Lupus ErythematosusNCT06559163 | Obexelimab | Active not recruiting | 2026-09-23Actual |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)NCT06564311 | Obexelimab | Active not recruiting | 2025-08-28Actual |
Names as written in the registry records.
NCT06559163 · Zenas BioPharma (USA), LLC
Before: Estimated. After: Actual.
Before: Sep 2026. After: 23 Sep 2026.
NCT06559163 · Zenas BioPharma (USA), LLC
Before: Estimated. After: Actual.
Before: Jun 2026. After: Sep 2026.
Before: Recruiting. After: Active not recruiting.
NCT07299019 · Zenas BioPharma (USA), LLC
Before: Not yet recruiting. After: Recruiting.
NCT05662241 · Zenas BioPharma (USA), LLC
Before: Estimated. After: Actual.
Before: 15 Nov 2025. After: 13 Nov 2025.
NCT07299019 · Zenas BioPharma (USA), LLC
Before: 330 participants (planned). After: 990 participants (planned).
NCT07067463 · Zenas BioPharma (USA), LLC
Before: Not yet recruiting. After: Recruiting.